Exai Bio
Latest round
- Series A
Last raised
- Dec 2021
Total raised
- $68M
Investors
- 3
About Exai Bio
Based in California, US, and founded in 2021, Exai Bio Inc. operates as a liquid biopsy company. Patrick Arensdorf (CEO) and Babak Alipanahi (Chief Scientific Officer) and Hani Goodarzi are the co-founders of the company. In December 2021, Exai Bio Inc. The company's platform provides clinical insight into cancer biology from non-invasive blood samples, allowing for early cancer detection and individualized treatment. Exai Bio's patented platform measures cell-free RNA profiles and analyses them with artificial intelligence and machine learning algorithms. It focuses on orphan non-coding RNA (oncRNA), which are short RNA sequences seen in malignancies but not in normal tissue.
Who invested in Exai Bio
3 investors across 1 round
See all investors in Exai Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 9, 2021
Amount
$68M
Investors
Questions about Exai Bio
Who invested in Exai Bio?
Exai Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Exai Bio raised?
Exai Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Exai Bio last raise money?
Exai Bio's most recent round on record is a Series A, in Dec 2021.
What does Exai Bio do?
Based in California, US, and founded in 2021, Exai Bio Inc.
Where is Exai Bio headquartered?
Exai Bio is headquartered in Palo Alto, US.
Which VCs invest in companies like Exai Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Exai Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Exai Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.